Treatment of benign prostatic hyperplasia through transurethral needle ablation (TUNA). Review of the literature and six years of clinical experience.
Following FDA clearance and the establishment of Medicare coverage, transurethral needle ablation (TUNA) has become an established and widely-adopted treatment method for BPH in the USA. Germany is lagging behind at present, though a change can also be recognized there. The lack of long-term data has often been criticized. This review presents an overview of clinical outcomes of TUNA, long-term results and patient selection criteria.
Braun
M
M
Department of Urology, University of Cologne, Cologne, Germany. Moritz.Braun@medizin.uni.koeln.de
Mathers
M
M
Bondarenko
B
B
Engelmann
U
U
D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors; D020728:Transurethral Resection of Prostate; D016055:Urinary Retention / Q000150:complications; D014563:Urodynamics